Chief Legal Officer and Secretary · ARS Pharmaceuticals, Inc. (SPRY)

Alexander Fitzpatrick

FY2023 is the first fiscal year CompBrief holds for Alexander Fitzpatrick as a named executive officer of ARS Pharmaceuticals; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$5,318,145

Salary $515,000Stock awards $0

2nd of 3 named executive officers at ARS Pharmaceuticals by FY2023 total.

3 named officers on file for ARS Pharmaceuticals, FY2023

Alexander Fitzpatrick’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 1 equity grant, each cited to its filing
  • SPRY’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how ARS Pharmaceuticals’s whole pay program stands against its peers

  • ARS Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on SPRY→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 26, 2024 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Alexander Fitzpatrick’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Alexander Fitzpatrick compensation by year

ARS Pharmaceuticals Summary Compensation Table · the one fiscal year held
In US dollars, as ARS Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023
Salary$515,000
Bonus$0
Stock awards$0
Option awards$4,641,000
Non-equity incentive$144,200
Pension and deferred compensation$0
All other$17,945
Total$5,318,145

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ARS Pharmaceuticals, Inc. DEF 14A filed April 26, 2024, accession 0000950170-24-049071, and prior-year filings. Open the filing on EDGAR.

How this page was built: the ARS Pharmaceuticals, Inc. filed document, accession 0000950170-24-049071. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2024.

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
Option525,000—$8.42

Per the Outstanding Equity Awards at Fiscal Year-End table in ARS Pharmaceuticals, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

6 Form 4 lines since the FY2023 proxy (filed April 26, 2024)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-06-12Sale10b5-13,355$10.0090,910
2026-01-02Grant or award derivative—240,000$0.00240,000
2025-05-20Exercise or conversion—100,000$5.58192,582
2025-05-20Sale—102,969$14.1089,613
2025-05-20Exercise or conversion derivative—100,000$0.00200,000
2025-01-02Grant or award derivative—152,300$0.00152,300

The 6 most recent of 6 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

ARS Pharmaceuticals’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Richard LowenthalPresident and Chief Executive Officer$10,039,096
Alexander Fitzpatrick · this pageChief Legal Officer and Secretary$5,318,145
Sarina TanimotoChief Medical Officer$4,791,493

The full ARS Pharmaceuticals compensation record

free company brief

This page is one person within ARS Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the ARS Pharmaceuticals proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ARS Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Alexander Fitzpatrick's compensation dossier · One-time report. No refunds.